Newron Pharmaceuticals S.p.A. Stock Deutsche Boerse AG
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.10 EUR | -0.38% |
|
-7.30% | -52.35% |
| 07-03 | Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment | MT |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
| Market Cap | 270M 308M 249M 231M 439M 29.43B 445M 2.98B 1.16B 14.44B 1.16B 1.13B 50.08B | P/E 2026 * |
-9.57x | P/E 2027 * | 35.1x |
|---|---|---|---|---|---|
| Enterprise Value | 309M 353M 284M 264M 501M 33.64B 508M 3.41B 1.33B 16.51B 1.32B 1.3B 57.25B | EV / Sales 2026 * |
28.5x | EV / Sales 2027 * | 6.35x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | -0.38% | ||
| 1 week | -7.30% | ||
| Current month | -7.30% | ||
| 1 month | -1.55% | ||
| 3 months | -21.85% | ||
| 6 months | -53.14% | ||
| Current year | -52.35% |
| 1 week | 12.7 |  | 13.95 |
| 1 month | 12.55 | | 13.95 |
| Current year | 12.55 | | 33.55 |
| 1 year | 7 | | 33.55 |
| 3 years | 4.2 | | 33.55 |
| 5 years | 1 | | 33.55 |
| 10 years | 1 | | 33.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 15/05/2012 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/01/2012 |
Filippo Moriggia
COO | Chief Operating Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 15/05/2012 |
Gillian Dines
BRD | Director/Board Member | - | 01/04/2023 |
Margarita Chavez
BRD | Director/Board Member | - | 17/04/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.38% | -7.30% | - | - | 308M | |
| +0.12% | +6.41% | +4.09% | +10.63% | 50.25B | |
| +0.40% | -1.37% | +401.69% | +625.15% | 40.39B | |
| -0.52% | +6.57% | +25.41% | -5.37% | 34.38B | |
| +3.97% | +6.71% | +26.06% | +63.36% | 34.4B | |
| -4.19% | -1.84% | +3.76% | +32.17% | 26.32B | |
| -2.40% | +1.60% | - | - | 16.64B | |
| +1.34% | +5.68% | +75.77% | +141.51% | 16.14B | |
| +1.25% | +1.49% | +15.43% | +22.63% | 13.71B | |
| +1.69% | +3.09% | +93.44% | +99.19% | 13.75B | |
| Average | +0.13% | +3.57% | +80.70% | +123.66% | 27.33B | |
| Weighted average by Cap. | +0.22% | +4.03% | +91.64% | +142.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.84M 12.38M 9.99M 9.27M 17.6M 1.18B 17.84M 120M 46.53M 580M 46.5M 45.48M 2.01B | 44.83M 51.19M 41.29M 38.33M 72.78M 4.88B 73.77M 494M 192M 2.4B 192M 188M 8.31B |
| Net income | -31.17M -35.6M -28.71M -26.65M -50.61M -3.4B -51.3M -344M -134M -1.67B -134M -131M -5.78B | 5.02M 5.74M 4.63M 4.29M 8.16M 547M 8.27M 55.38M 21.55M 269M 21.54M 21.07M 931M |
| Net Debt | 38.68M 44.17M 35.63M 33.07M 62.8M 4.21B 63.65M 427M 166M 2.07B 166M 162M 7.17B | 14.72M 16.8M 13.56M 12.58M 23.89M 1.6B 24.22M 162M 63.15M 787M 63.11M 61.72M 2.73B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/07/26 | €12.70 | -3.42% | 0 |
| 06/07/26 | €13.15 | -5.40% | 0 |
| 03/07/26 | €13.90 | +3.73% | 0 |
| 02/07/26 | €13.40 | -3.94% | 0 |
| 01/07/26 | €13.95 | +1.82% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
